Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism
Sponsor
GAAD Medical Research Institute Inc. (Other)
Overall Status
Unknown status
CT.gov ID
NCT00573573
Collaborator
(none)
2
1
1
30
0.1
Study Details
Study Description
Brief Summary
A study to determine the possibility of using far infrared radiation to treat Hyperparathyroidism.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
Overactive parathyroid glands secrete an excess of parathyroid hormones, resulting in increased levels of calcium in the blood stream, which can lead to weakening of the bones and to kidney stones.
We are postulating that the non-invasive energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to stop the over secretion of the parathyroid hormones and normalize the body's metabolic functions.
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
2 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism.
Study Start Date
:
Jan 1, 2007
Anticipated Primary Completion Date
:
Mar 1, 2009
Anticipated Study Completion Date
:
Jul 1, 2009
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: 1
|
Radiation: Far Infrared Radiation
Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
|
Outcome Measures
Primary Outcome Measures
- The primary end point is to determine the therapeutic effects of far infrared radiation on Hyperparathyroidism. [2 years]
Secondary Outcome Measures
- Effect of far infrared radiation treatment on other immune deficiency diseases like thyroidism and diabetes [2 years]
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Persons with parathyroid disease
Exclusion Criteria:
- None
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The Centre for Incurable Diseases | Toronto | Ontario | Canada | M4V 1L5 |
Sponsors and Collaborators
- GAAD Medical Research Institute Inc.
Investigators
- Study Director: Ken Nedd, M.D., GAAD Medical Research Institute Inc.
- Study Chair: Kwasi Donyina, Ph.D., GAAD Medical Research Institute Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00573573
Other Study ID Numbers:
- GAAD-HT-CTP1
First Posted:
Dec 14, 2007
Last Update Posted:
Mar 24, 2009
Last Verified:
Mar 1, 2009
Keywords provided by ,
,
Additional relevant MeSH terms: